Official Title
At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19
Brief Summary

This is an open-label, pragmatic, single-dose study using matched controls in participants with mild to moderate COVID-19. Participants will track for developing symptoms while at home and upon reporting of symptoms will test for COVID-19. If positive for COVID-19, a one-time at-home infusion of Bamlanivimab (LY3819253) will be provided by Optum Infusion. Participants will then track for 28 days to assess for any additional medical care needed or if hospitalization was required.

Terminated
COVID19

Drug: bamlanivimab

Participants that test positive for COVID-19 may be eligible to receive an in-home infusion of bamlanivimab by a registered nurse. This infusion will last approximately 1 hour followed by 1 hour of observation.

Eligibility Criteria

Inclusion Criteria:

- UnitedHealthcare member

- confirmed COVID-19 positive

- located in an area where Bamlanivimab (LY3819253) is available for infusion

Exclusion Criteria:

- current (from first symptom report) hospitalization for COVID-19

- prior administration of Bamlanivimab or other COVID-19 therapies

- previous COVID-19 diagnosis

- prior receipt of a COVID-19 vaccine

- not authorized for patient use per the EUA

Eligibility Gender
All
Eligibility Age
Minimum: 65 Years ~ Maximum: N/A
Countries
United States
Locations

QueryLab
Minnetonka, Minnesota, United States

Dan Griffin, MD, PHD, Principal Investigator
ProHealth New York - UnitedHealth Group

Daniel Griffin
NCT Number
Keywords
COVID19
bamlanivimab
UnitedHealth
MeSH Terms
COVID-19
Bamlanivimab